

## Hormone Therapy for Gender Affirmation

Charts prepared September 2023.

Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r +DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX
<b>Feminizing hormones</b>										
<b>Conjugated estrogens</b> <i>Premarin</i>	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
<b>Estradiol</b> <i>Multiple brand names</i>	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
<b>Ethinylestradiol</b> <i>Multiple brand names</i>	↔	↔	↑ <sup>b</sup>	↔	↔ <sup>b</sup>	↔ <sup>b</sup>	↔	↔	↔	↔ <sup>b</sup>
<b>Medroxyprogesterone</b> <i>Provera</i>	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Micronized Progesterone</b> <i>Prometrium, Utrogestan</i>	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
<b>Androgen blockers</b>										
<b>Cyproterone acetate</b> <i>Androcur, Cyprostat</i>	↑↑	↑↑	↑↑	↑	↑	↑	↔	↔	↔	↔
<b>Dutasteride</b> <i>Avodart</i>	↔	↔	↔	↔	↑ <sup>c</sup>	↑ <sup>c</sup>	↔	↔	↔	↔
<b>Finasteride</b> <i>Propecia, Proscar</i>	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
<b>Goserelin acetate</b> <i>Zoladex</i>	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Leuprorelin acetate</b> <i>Leuprolide, Lupron, Eligard, Prostap</i>	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Spirololactone</b> <i>Aldactone, CaroSpir</i>	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Triptorelin</b> <i>Decapeptyl, Triptodur</i>	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Androgens</b>										
<b>Testosterone</b> <i>Multiple brand names</i>	↔	↔	↔	↔	↑ <sup>d</sup>	↑ <sup>d</sup>	↔	↔	↔	↔
<b>Misc.</b>										
<b>Minoxidil</b> <i>Regaine</i>	↔	↔	↔	↔	↑ <sup>e</sup>	↑ <sup>e</sup>	↔	↔	↔	↔

## Colour Legend

<span style="background-color: #d9ead3; border: 1px solid black; display: inline-block; width: 15px; height: 10px;"></span>	No clinically significant interaction expected.
<span style="background-color: #f2dede; border: 1px solid black; display: inline-block; width: 15px; height: 10px;"></span>	These drugs should not be coadministered.
<span style="background-color: #fff2cc; border: 1px solid black; display: inline-block; width: 15px; height: 10px;"></span>	Potential interaction which may require a dosage adjustment or close monitoring.
<span style="background-color: #d9ead3; border: 1px solid black; display: inline-block; width: 15px; height: 10px;"></span>	Potential interaction predicted to be of weak intensity.

## Text Legend

↑	Potential increased exposure of the hormone therapy	↑	Potential increased exposure of HCV DAA
↓	Potential decreased exposure of the hormone therapy	↓	Potential decreased exposure of HCV DAA
↔	No significant effect		

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies.

- Close monitoring is recommended, as the overall effect and clinical significance is difficult to predict.
- Coadministration is contraindicated due to increased ALT levels.
- A reduction of the dutasteride dosing frequency can be considered if side effects are noted.
- Monitoring or dose adjustment may be required.
- Monitoring may be required of cardiac parameters and for increased side effects.

## References

- Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. UCSF Transgender Care, June 2016. <https://transcare.ucsf.edu/guidelines>.
- Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, E Coleman, AE Radix, WP Bouman et al. 2022, International Journal of Transgender Health, 23: S1-253. <https://doi.org/10.1080/26895269.2022.2100644>
- Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. WC Hembree, PT Cohen-Kettenis, L Gooren et al. 2017, J Clin Endocrinol Metab, 102(11):3869-3903.

Abbreviations: DCV Daclatasvir ELB/GZR Elbasvir/Grazoprevir G/P Glecaprevir/Pibrentasvir LED Ledipasvir OBV/PTV/r +DSV Ombitasvir/Paritaprevir/Ritonavir +Dasabuvir  
RDV Ravidasvir SOF Sofosbuvir VEL Velpatasvir VOX Voxilaprevir

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.